Malignant Pleural Mesothelioma - nivolumab - PD-L1 overexpression

Association details:

Biomarker:	PD-L1 overexpression
Cancer:	Malignant Pleural Mesothelioma
Drug:	Opdivo (nivolumab) (PD1 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C4 – Case Studies

Source:

Respirol Case Rep

Title:

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1

Published date:

02/14/2020

Excerpt:

We report herein a case of sarcomatoid malignant pleural mesothelioma (MPM) with high PD-L1 expression...After the nivolumab treatment, CT showed a significant reduction in pleural tumours with a marked improvement in symptoms.

DOI:

10.1002/rcr2.536